Document:

EX-10.6

 Exhibit 10.6 
 NOTE:
PORTIONS OF THIS EXHIBIT INDICATED BY “[****]” ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 
 MASTER SERVICES AGREEMENT 

This Master Services Agreement (“Agreement”) is entered into as of January 30, 2015 (the “Effective Date”) by
and between TherapeuticsMD, Inc., a Nevada corporation with an office at 951 Broken Sound Parkway NW, Suite 320, Boca Raton, FL 33487 (the “Client”), and Sancilio & Company, Inc., a Delaware corporation with an office at
3874 Fiscal Court, Suite 200, Riviera Beach, Florida 33404 (“SCI”). The Client and SCI are referred to singly as “Party” and jointly as “Parties” throughout this Agreement. 

W I T N E S S E T H 
 WHEREAS, SCI is in
the business of providing certain preclinical and clinical drug development and formulation, drug product stability, analytical, manufacturing and regulatory consulting services for the pharmaceutical industry (the “Services”);
and 
 WHEREAS, SCI represents that it has the necessary personnel, expertise, facilities and experience to provide such Services to the
Client; 
 WHEREAS, SCI and Client desire to enter into this Agreement to provide the terms and conditions upon which Client may engage SCI,
from time to time and as agreed to by SCI, to provide services for individual projects in accordance with mutually agreed upon SOWs, Change Orders and/or Letters of Authorization (each as defined below) specifying the details of the services and the
related terms and conditions. The SOWs, Change Orders and Letters of Authorization are referred to herein as “Project-Specific Agreements.” 

NOW THEREFORE, for and in consideration of the mutual covenants and agreements set forth hereinafter and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto do hereby agree as follows: 
 ARTICLE I 

SCOPE OF AGREEMENT AND STATEMENTS OF WORK/CHANGE ORDERS 

1.1 This Agreement sets forth the basic terms and conditions that shall apply to all Projects (as defined below) that are the subject of Project-Specific
Agreements entered into pursuant to this Agreement. 
 1.2 The specific duties and responsibilities for each project under this Agreement (each, a
“Project”) shall be separately negotiated and specified in a statement of work on terms and in a format mutually agreed upon and executed by the Parties (each such writing, a “SOW”). Each SOW shall include
(i) the scope and specification of the Project; (ii) deliverables and timelines; (iii) any performance metrics; and (iv) a budget and payment schedule. Any material change in the details of a SOW shall require a written amendment
to the SOW, mutually agreed upon and executed by the Parties (a “Change Order”). 

  
 1 

 1.3 Any and all Project-Specific Agreements issued and executed pursuant to this Agreement will be made
part hereof and incorporated herein by reference, and shall be subject to the terms and conditions set forth in this Agreement. Any and all Project-Specific Agreements shall also be subject to the terms and conditions set forth in the quality
requirements agreement to be executed by the parties in concert with this present Agreement and attached hereto as Exhibit A (the “Quality Agreement”), unless otherwise expressly set forth in the Project-Specific
Agreements. To the extent there is any conflict between the provisions of this Agreement, the Quality Agreement and/or a Project-Specific Agreement, the terms and conditions of this Agreement and those of the Project-Specific Agreement shall be read
in accord wherever possible; where certain provisions set forth in the Project-Specific Agreements are in more exacting or detailed form over corresponding provisions in this Agreement, the Project-Specific Agreement shall govern; but where such
certain provisions are otherwise ambiguous or unclear over the corresponding Agreement provisions, the Agreement provisions shall govern. Set forth on Exhibit B is a list of currently active Statements of Work and Change Orders, as
well as other active agreements between the Parties. 
 1.4 Services provided by SCI shall comply with all applicable Good Laboratory Practices,
current Good Manufacturing Practices, Good Clinical Practices, and all other United States governmental and regulatory standards, specifications and guidelines, as specified in the Quality Agreement. 

1.5 The Parties understand that SCI shall use commercially reasonable efforts to initiate, conduct and complete the Services as set forth in a Project-Specific
Agreement in a timely fashion. The Client understands and agrees that completing the Services as set forth in a Project-Specific Agreement assumes the full cooperation of the Client, as well as any necessary third parties. 

1.6 For clarity, and notwithstanding Section 1.5, it is understood that Client has a strategic objective to start certain U.S. clinical studies pursuant
to the timetables set forth in certain SOWs, provided that such deadlines may be adjusted to account for regulatory delays and patient recruitment delays, or as mutually agreed upon in writing by the Parties. The Parties further agree that time and
quality are of the essence in this Agreement and associated SOWs, Change Orders, and Letters of Authorization. 
 ARTICLE II 

PROJECT IMPLEMENTATION 
 2.1 Prior
to SCI’s commencement of Services hereunder, the Parties shall execute one or more Project-Specific Agreements. The Client’s execution of a Project-Specific Agreement will be deemed its authorization for SCI to proceed under the terms and
conditions of this Agreement and the Quality Agreement, as applicable. 

  
 2 

 2.2 SCI shall utilize commercially reasonable efforts to provide the Services as agreed in any Project-Specific
Agreements and, if necessary, any associated Change Order. 
 2.3 The Parties recognize that in certain instances, the Client may wish SCI to commence
Services prior to the formal execution of a SOW authorizing such Services. In such circumstances, the Client may authorize SCI in writing (a “Letter of Authorization”) to commence specified Services pending execution of the relevant
SOW. A Letter of Authorization shall specify the Services to be performed and a dollar limitation for the performance of such Services. 
 2.4 SCI
shall use commercially reasonable efforts to anticipate the scope of activities necessary to complete Services established by a Project-Specific Agreement. However, Project-Specific Agreements constitute both Parties’ informed estimate of those
Services necessary to satisfactorily complete a Project and are based upon the Parties’ current knowledge of the factual situation, as well as the current regulatory environment. Therefore, the scope of proposed Services may require
modification of the Project-Specific Agreements during the course of performance. In the event additional or different Services are required, the Client’s authorized representative, as set forth in Article VIII, may in writing authorize SCI to
perform additional or different Services, wherein such additional or different services shall become effective only upon a Change Order executed in writing by both Parties. 

2.5 SCI will use commercially reasonable efforts to complete the agreed upon Project according to the applicable terms set forth in any executed
Project-Specific Agreement. However, the Parties recognize that the Services to be provided hereunder are not subject to precise advance determination. In the event unforeseen difficulties arise, SCI shall inform the Client, outlining the basis of
any such difficulties. In such event, the Parties agree to enter into good faith negotiations regarding the possibility of amending applicable terms under the Project-Specific Agreement to address such defined difficulties. In no event however, will
any such difficulties, per se, amend or alter the terms of this Agreement or any related Project-Specific Agreement, absent the subsequent mutual agreement of both Parties in writing. 

ARTICLE III 
 PAYMENT
FOR SERVICES RENDERED 
 3.1 The Client agrees to pay for Services as agreed upon in a Project-Specific Agreement executed by the Client and
delivered to SCI. 
 3.2 The Client shall reimburse SCI for reasonable and customary out-of-pocket expenses, including any appropriate handling fees
(not including any supplies and services as set forth in Article 3.3 herein) incurred in connection with the performance of the Services set forth in the Project-Specific Agreements provided that SCI provides the Client with documentation of
such approved expenditures, if requested. Unless otherwise agreed by the Parties in writing in a Project-Specific Agreement, SCI shall invoice the Client for such expenses at cost. 

3.3 Unless otherwise agreed by the Parties in writing in a Project-Specific Agreement, SCI shall charge the Client a five percent (5%) handling fee for
all supplies, materials or services acquired for or on behalf of the Client to satisfactorily complete the Services as set forth in the Project-Specific Agreement. 

3.4 [reserved] 

  
 3 

 3.5 If the Client delays or temporarily halts a Project after such Project has commenced for reasons beyond the
commercially reasonable control of SCI, the Parties will negotiate a reasonable fee, payable on a monthly basis, to compensate SCI for reasonable expenses incurred related to such delay, including the storage of Client’s samples and materials.
SCI shall provide the Client with an itemized invoice describing such expenses. The Client will pay the expenses associated with such invoices in accordance with Article 3.6 herein. 

3.6 Unless otherwise agreed by the Parties in writing, SCI shall invoice the Client on a calendar month basis for Services rendered, for agreed upon costs,
milestone, and other payment terms and conditions as set forth in any Project-Specific Agreement. Invoices are due and payable net thirty (30) days after Client’s receipt of invoice. All payments to SCI shall be made in U.S. dollars.
Invoice balances not remitted within thirty (30) days of receipt of invoice shall be subject to a one and one-half percent (1.5%) per month interest charge. Should any part of the invoice be in dispute, the Client shall pay any undisputed
amount according to the terms and conditions described herein while said dispute is being resolved. 
 ARTICLE IV 

INTELLECTUAL PROPERTY 
 4.1 Any
invention, trade secret or know-how and any materials, documents, programs or information belonging to Client and supplied to SCI by Client pursuant to this Agreement shall remain the property of Client. Any invention, trade secret or know-how and
any materials, documents, programs or synthesis information belonging to SCI prior to the date of this Agreement, or developed by SCI independently of this Agreement, i.e. not falling within Article 4.2 below, shall remain the property of SCI.

 4.2 Any inventions (whether or not patentable), processes, techniques, improvements, discoveries, designs, formulae, copyright, trademark, trade
secrets, know-how, developments, confidential information, computer software, data and documentation, and all similar intellectual property rights created, discovered or reduced to practice by SCI solely or jointly in the course of performing the
Services or other work performed under a Project (collectively, “Project IP”) SCI shall notify the Client promptly when it has made, created or otherwise invented any Project IP. SCI agrees to assign and hereby does assign to Client
all Project IP (including any patent and all other intellectual property rights therein), and Project IP shall be deemed the Confidential Information of Client for purposes of Article V below. SCI will, at the expense and the written request of the
Client, take all reasonable steps and execute all documents as the Client may reasonably request to transfer to and vest in the Client the ownership and registration of all intellectual property rights that may exist in such Project IP. 

4.3 With respect to Project IP, SCI will not knowingly or negligently incorporate or use therein any invention, discovery, process, technology or
information that (a) is subject in whole or in part to a claim of any patent application or issued patent that is owned or controlled by SCI, but not assigned to Client pursuant to Article IV (“SCI Background Patent Rights”),
(b) is subject in whole or in part to a claim of any patent or patent application of a third party, or (c) incorporates any SCI processes, inventions, techniques, know-how, or trade secrets that are owned or controlled by SCI, but not
assigned to Client pursuant to Article IV (“SCI Background Know-How”). In the event any Project IP incorporates or requires the use of SCI  

  
 4 

 
Background Patent Rights or SCI Background Know-How (collectively, “SCI Proprietary Technology”), SCI shall grant and grants to Client a non-exclusive, non-transferable,
worldwide, royalty-free, fully paid license to use such SCI Background Know-How and SCI Proprietary Technology in connection with the procurement, use, sale and marketing of any commercial product or process deriving from this Agreement. 

4.4 The Client acknowledges that SCI is in the business of providing Services for a variety of organizations other than the Client. Accordingly, nothing in
this Agreement shall preclude or limit SCI from providing Services or developing materials for itself or other clients, or from utilizing the general knowledge gained during the course of its performance hereunder to perform similar Services for
other clients, provided that such provision of Services or development of materials do not constitute a breach of confidentiality under Article V herein. 

ARTICLE V 

CONFIDENTIALITY 
 5.1 During
the performance of Services and the Term of this Agreement, each Party may receive from the other Party confidential or proprietary information, including: information concerning Client’s regulatory submissions; pre-clinical and clinical
trials; other data, testing and research techniques; inventions, materials, processes, practices; product research, development and acquisition plans; acquisitions, mergers, divestitures and the like; other business and marketing plans; and other
proprietary and trade secrets and like information (collectively “Confidential Information”). Client agrees that it will only provide such Confidential Information to the extent that it is required by SCI to perform Services. For
the avoidance of doubt, the following shall in all cases be treated as Confidential Information hereunder: (a) all samples of chemical compounds and data related thereto, (b) all Confidential Information provided under the Parties’
prior Non-Disclosure Agreement dated December 1, 2011, (c) all Project IP, data, results or other information as otherwise developed or generated by SCI for the Client, or any methodologies, technology, or assays developed by SCI for the
Client, and (d) all other Project IP, data, results or other Information otherwise arising under or relating to this Agreement. 
 5.2 The
Parties will each use the same care to prevent disclosing to third Parties the Confidential Information of the other Party as it employs to avoid disclosure, publication or dissemination of its own information of a similar nature, but in no event
less than a reasonable standard of care. Neither Party will use the Confidential Information of the other Party except in the performance of its obligations and exercise of its rights under this Agreement. 

5.2.1 For clarity, each Party agrees that without the express written consent of the other Party, it will not itself use, or provide to,
disclose to, or permit any third party to use said Confidential Information. The Parties agree to take commercially reasonable and appropriate measures to safeguard Confidential Information from theft, loss or negligent disclosure to others and to
limit internal access to Confidential Information to those of its employees, consultants, agent or subcontractors who reasonably require such access in order to accomplish performance of the Services. Each Party’s employees, consultants, agents
or subcontractors who have or will have access to Confidential Information have signed or, prior to disclosure of Confidential Information, will sign a confidentiality agreement with provisions no less protective than this Article V. Either Party
disclosing Confidential Information under this Agreement assumes full responsibility for the acts or omissions of such third parties, no less than if the acts or omissions were those of the disclosing Party. 

  
 5 

 5.2.2 Unless otherwise consented to by the disclosing Party in writing or provided for in a
Project-Specific Agreement, the receiving Party agrees not to analyze for chemical composition any samples or materials provided by the disclosing Party, nor to allow or cause any such samples or materials to be released to third parties for
analysis. 
 5.2.3 Neither Party shall use or disclose to the other Party any Confidential Information of a third party except as approved in
advance in writing by the receiving Party. 
 5.2.4 Each Party agrees to notify the other Party promptly of the date of, and the
circumstances involved in, the loss or unauthorized disclosure of any Confidential Information of the other Party. 
 5.3 Notwithstanding the foregoing,
Confidential Information will not include any information which either Party can demonstrate was: 
 (a) at the time of disclosure to it, in
the public domain; 
 (b) after disclosure to it, published or otherwise becomes part of the public domain through no fault of the receiving
Party; 
 (c) without a breach of duty owed to the disclosing Party, is in the possession of the receiving Party at the time of disclosure to
it; 
 (d) received after disclosure to it from a third party who had a lawful right to and, without a breach of duty owed to the disclosing
Party, did disclose such information to it; or 
 (e) independently developed by the receiving Party without reference to Confidential
Information of the Disclosing Party. 
 5.3.2 Furthermore, either Party may disclose the other Party’s Confidential Information to the
extent required by law or order of a court or governmental agency or to enforce this Agreement. However, the recipient of such Confidential Information must give the other Party prompt notice and make a reasonable effort to obtain a protective order
or otherwise protect the confidentiality of such Confidential Information, all at such other Party’s cost and expense. 
 5.4 Upon expiration or
termination of Agreement or completion or termination of any Project-Specific Agreement, and at the written direction of the other Party, each Party will promptly return all Confidential /Information of the other Party, including any documents
prepared by SCI that contain such information, as further set forth in Article VIII. SCI may retain a single archival copy of the Confidential Information for the sole purpose of determining the scope of obligations incurred under this Agreement.
The obligations of this Article V shall apply to all Confidential Information was disclosed to the receiving Party, whether such Confidential Information was disclosed before or after the Effective Date, and survive for a period of five
(5) years from the expiration or termination of this Agreement. 

  
 6 

 5.5 The Parties agree that they shall not use the other Party’s name, or disclose the existence of this
Agreement or any matters relating to the Services provided hereunder in any advertising, promotion, written articles or communications without the prior written consent of the other Party, such consent not to be unreasonably withheld. 

ARTICLE VI 

REPRESENTATION, WARRANTIES, AND COVENANTS 

6.1 SCI’s Representations. SCI represents and warrants to Client as of the Effective Date that: 

(i) the execution and delivery of this Agreement and the performance of the transactions, rights and licenses contemplated hereby have been
duly authorized by all appropriate SCI corporate action; 
 (ii) SCI has the full right and authority to enter into this Agreement, and this
Agreement is a legal and valid obligation binding upon SCI and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by the terms set forth herein, and does not conflict with any agreement,
instrument or understanding to which SCI is a party or by which it is bound; 
 (iii) SCI has the full right and legal capacity to grant the
rights granted to Client hereunder without violating the rights of any third party; and 
 (iv) SCI is the owner of the SCI Technology and,
to SCI’s actual knowledge, no third party claims any ownership of the SCI Technology. 
 In no event shall either party be liable for any consequential,
special, exemplary, incidental or other indirect damages or lost profits in any way associated with this Agreement, regardless of the form of action. 
 6.2
Client’s Representations. Client represents and warrants to SCI as of the Effective Date that: 
 (i) the execution and delivery
of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate Client corporate action; 

(ii) Client has the full right and authority to enter into this Agreement, and this Agreement is a legal and valid obligation binding upon
Client and enforceable in accordance with its terms, and execution, delivery and performance of this Agreement by the terms set forth herein, and does not conflict with any agreement, instrument or understanding to which Client is a party or by
which it is bound; 

  
 7 

 (iii) Client has the full right and legal capacity to grant the rights granted to SCI hereunder
without violating the rights of any third party; and 
 (iv) Client is the owner of the TherapeuticsMD Technology and, to Client’s
actual knowledge, no third party claims any ownership of the TherapeuticsMD Technology. 
 6.3 Product Warranty. SCI represents and warrants that:

 (i) Any drug product supplied by SCI shall meet the product specifications set forth in the applicable Project-Specific Agreement, and
further represents and warrants that the product specification and the methodologies used to synthesize any drug product shall meet all requirements that are necessary to conduct any clinical trials specified in any applicable Project- Specific
Agreement and shall support any of Client’s (or its designee’s) contemplated New Drug Application to market a drug product in the U.S. pursuant to the then applicable U.S. regulatory requirements. SCI will use its Commercially Reasonable
best efforts to supply any drug product in the quantities, at the times and at the locations designated by Client in filly applicable Product-Specific Agreement. 

(ii) Any drug product that is part of any shipment or delivery made to Client pursuant to this Agreement will not, at the time of shipment to
Client by SCI, be adulterated or misbranded within the meaning of the FD&C Act. 
 ARTICLE VII 

INDEMNIFICATION 
 7.1
Indemnification by Client. Subject to Section 7.4 below, the Client shall indemnify and hold harmless SCI, its agents, employees, directors and Affiliates from any loss expense and liability, including reasonable attorney’s fees,
arising from any claim suit or proceeding to the extent resulting from Client’s negligent or willful misconduct regarding use or provision of (a) products and services using the Project IP, or (b) other materials or processes supplied
or disclosed to Client in the course of providing Services pursuant to this Agreement, except to the extent the claim, suit or proceeding is subject to SCI’s indemnification obligations in Section 7.2 below. 

7.2 Indemnification by SCI. Subject to Section 7.4 below, SCI shall indemnify and hold harmless the Client, its agents, employees, directors and
Affiliates from any loss, expense and liability, including reasonable attorney fees arising out of SCI’s negligence or willful misconduct in the course of providing Services pursuant to this Agreement. 

7.3 Indemnification for Patent Infringement. Subject to Section 7.4 below, if SCI is subject to allegations of or sued for patent infringement or
infringement of other intellectual property rights anywhere in the world with respect to its pre-clinical or clinical manufacture and distribution of any drug product pursuant to the terms of this Agreement or any Project-Specific Agreement
initiated by a third party asserting infringement of its rights with respect to the active ingredients in a drug product of combinations thereof, or if Client is subject to allegations of or sued for patent infringement or infringement of other
intellectual property rights anywhere in the world initiated by a third party asserting infringement of its right with respect to the manufacturing methods or materials used by SCI in its manufacture of drug product, then Client

  
 8 

 
or SCI, as the case may be, will indemnify the other and hold such indemnified Party harmless and defend against such suits. The foregoing in this subsection 7.3 notwithstanding, Client shall not
be liable to SCI under indemnity of such suit is based on the manufacture or use of a drug product by SCI in a manner not specified by the terms of this Agreement or a Project-Specific Agreement. 

7.4 A party that intends to claim indemnification (the “Indemnitee”) under Section 7.1, 7.2 or 7.3 shall promptly notify the other
party (the “Indemnitor”) in writing of any claim, complaint, suit, proceeding or cause of action with respect to which the Indemnitee intends to claim such indemnification (for purposes of this Article VII, each a
“Claim”) and the Indemnitor, shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense
and/or settlement of such Claim. The Indemnitor shall not settle any Claim without the consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed. The indemnitee, and its employees, at the Indemnitor’s request and
expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered by this indemnification. 

7.5 Each Party shall be responsible for the safety of its own employees and agents with respect to the handling or use of materials involved in the performance
of this Agreement and any Project-Specific Agreement hereunder. 
 7.6 SCI shall perform the Services hereunder as an independent contractor, and nothing
contained in this Agreement or otherwise shall be deemed to create any other relationship, including employment, partnership, agency or joint venture, between the Parties. The Parties acknowledge that services performed are solely within the control
of SCI and the provisions of this Agreement shall not be construed as authorizing the Client to exercise any control or direction over the employees or agents of SCI in connection with this Agreement. Neither Party to this Agreement shall have any
authority to employ any person as agent or employee for or on behalf of the other, or to bind, or attempt to bind, the other to any obligation with any third party. 

7.7 “Affiliate” shall mean any corporation, company, partnership, joint venture and/or firm, which controls, is controlled by or is
under common control with a Party. For purposes of this Article VII “control” shall mean (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote
for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to substantially direct the management and policies of such
non-corporate entities. 
 ARTICLE VIII 

TERM AND TERMINATION 
 8.1
Unless sooner terminated in a manner herein provided, this Agreement shall continue until December 31, 2015 (hereinafter the “Term”). The Parties may extend this Agreement by written mutual agreement at least sixty
(60) days prior to the expiration of the Term. 

  
 9 

 8.2 This Agreement, the Quality Agreement and any corresponding Project-Specific Agreement then in effect may be
terminated by (i) either Party upon written notice for cause in the event of a failure by the other Party to substantially perform any material obligation that, through no fault of the Party initiating the termination, remains uncured thirty
(30) days after receipt of prior written notice; (ii) Client upon thirty (30) days written notice to SCI or (iii) either Party upon dissolution, insolvency or bankruptcy as set forth in 8.2.1 below. 

8.2.1 This Agreement may be terminated by any one Party in the event that the other Party: (i) applies for or consents to the appointment
of a receiver, conservator, trustee, liquidator, custodian or other judicial representative for itself or any substantial portion of its assets or properties; (ii) admits in writing its inability to pay its debts as they become due;
(iii) makes an assignment for the benefit of its creditors; (iv) has an order for relief filed by a bankruptcy court for or against it or is adjudicated insolvent; or (v) files a voluntary petition admitting bankruptcy or an
arrangement with creditors or takes advantage of any bankruptcy, insolvency, readjustment or debt, dissolution or liquidation law or statute, files an answer admitting the material allegations of a petition filed against it in any proceeding;
(vi) or a decree is entered by any court of competent jurisdiction approving a petition, seeking reorganization or appointing a receiver, conservator, trustee, liquidator, custodian or other judicial representative, and such order, judgment or
decree continues in effect for a period of sixty (60) consecutive days. 
 8.3 In the event of a termination of this Agreement pursuant to
Section 8.2, with the exception of material breach by SCI, the Client shall be obligated to pay to SCI the cost of all Services in process or completed, as set forth in the relevant Project-Specific Agreements currently in effect at the time of
termination, in accordance with the terms and conditions set forth in this Agreement. Client shall also be obligated to pay for all unused supplies and materials ordered by SCI in connection with performance of the Services. SCI shall use
commercially reasonable efforts to minimize the costs associated with the cessation of any such Project-Specific Agreements. 
 8.4 Client may terminate any
Project-Specific Agreement without terminating this Agreement by providing SCI written notice. In the event of a termination of a Project-Specific Agreement, SCI shall receive full payment for all Services actually performed through the effective
date of termination, including any appropriate delay or cancellation fees as may be set forth in the Project-Specific Agreements. In accordance with the Client’s written instructions, SCI shall use commercially reasonable efforts to transfer
the results, information, documents, Project IP, and other property and information relating to or resulting from such Project-Specific Agreement to the Client or its agent. The Client shall pay reasonable costs incurred by SCI that are necessary or
reasonably required in connection with the orderly cessation of such Project-Specific Agreements, not to exceed 1/2 of the cost of the Project that is the subject of the terminated Project-Specific Agreement(s). In no event shall the total amount
calculated pursuant to this Section 8.4 exceed the total amount of payments set forth in the budget for such Project-Specific Authorization. Within thirty (30) days after the termination date of any Project-Specific Agreement, SCI shall
refund to Client any amounts paid by Client to SCI in excess of the calculated amount described herein. 

  
 10 

 8.5 The accrued rights and obligations of the Parties shall not be affected by any termination of this Agreement.
Furthermore, upon termination of this Agreement for any reason by any party, and irrespective of any claims, rights or remedies Client or SCI may have against the other Party under this Agreement other than for payments then due and payable pursuant
to the terms of any Project-Specific Agreement, SCI expressly agrees to deliver immediately to Client: all work product (including partial results, drafts and notes, in all tangible media, including electronic format, works in progress and patents,
know-how and other intellectual property created or worked on by SCI in, and relating directly to, the performance of its obligations under this Agreement; (ii) any inventory of drug product or precursors thereto; (iii) any materials
received from Client or other sources in order for SCI to perform its obligations under this Agreement; (iv) all Equipment procured by SCI shipped in accordance with Client’s instructions at Client’s cost and risk; (v) a report
by SCI to Client in reasonable detail outlining the status of the foregoing, (vi) any other outstanding reports or documentation required under the Agreement, SCI further agrees to execute documents as Client may reasonably request and to
transfer any Drug Master Files in SCI’s possession to Client or its designee all at Client’s cost, to the extent such actions are not already required by this Agreement or any Project-Specific Agreement, so that such termination or the
pursuit of any such claims, rights and remedies shall not interfere with the timely development of any drug product by Client in its absolute discretion. 

ARTICLE IX 

CORRESPONDENCE AND NOTICE 
 9.1
Until advised in writing to the contrary by either Party, all communications and notices related to this Agreement shall be effective upon receipt and shall be addressed to: 
  

	 	CLIENT:	TherapeuticsMD, Inc. 

	 	 	951 Broken Sound Parkway NW, Suite 320 

	 	 	Boca Raton, Florida 33487 

	 	 	(Attention: Chief Financial Officer) 

	 	 	Fax: 561-431-3389 

  

	 	SCI:	Sancilio & Company, Inc. 

	 	 	3874 Fiscal Court, Suite 200 

	 	 	Riviera Beach, Florida 33404 

	 	 	(Attention: Chief Legal Officer) 

	 	 	Fax: 561-847-2312 

 9.2 All communications and notices related to a Project-Specific Agreement shall be
addressed to the appropriate individual for each Party as set forth in such Project-Specific Agreement. 
 ARTICLE X 

RECORDS AND AUDITS 
 10.1 SCI agrees
to maintain records of all Services performed under this Agreement in accordance with the United States Food and Drug Administration’s archival guidelines. The Client may review the records of SCI relating to the Services performed and the
expenses 

  
 11 

 
incurred to assure compliance with all provisions of this Agreement, provided that such inspection may take place (i) only upon reasonable prior written notice (not less than ten
(10) business days) and during SCI’s regular business hours, and (ii) at the Client’s sole cost and expense. The Client shall be invoiced for any reasonable and actual incidental expenses SCI incurs resulting from any such
review, to the extent such review exceeds four (4) business days each calendar year. 
 10.2 Upon reasonable prior written notice (not less than fifteen
(15) business days) and during regular business hours the Client may, at its own cost and expense, review SCI’s quality control procedures and records, with a representative of SCI present. The Client shall be invoiced for any reasonable
and actual incidental expenses SCI incurs resulting from such review, to the extent such review exceeds one (1) review each calendar year. 
 10.3 In
the event of an Inspection by any governmental or regulatory authority concerning the Services performed hereunder, SCI shall notify the Client promptly upon learning of such an inspection, shall supply the Client with copies of any correspondence
or portions or correspondence relating to the Services and shall inform the Client of the general findings and outcomes of such inspections. The Client shall be invoiced for any reasonable and actual incidental expenses SCI incurs resulting from
such review. 
 ARTICLE XI 

MISCELLANEOUS 
 11.1
Certification. SCI represents, warrants and certifies that neither it, nor its Affiliates, nor any of their respective directors, officers, principals, employees and agents was or is debarred, suspended, proposed for debarment or otherwise
determined to be ineligible to participate in the drug industry, federal health care programs under or convicted of a criminal offense related to the provision of health care items or services the United States Food, Drug and Cosmetic Act, (21
U.S.C. 301 et seq.), and that it has not and will not use in any capacity the services of any entity or person debarred under such law with respect to Services to be performed under this Agreement. In the event that SCI, or any of its Affiliates,
directors, officers, principals, employees, or agents becomes or is debarred, suspended, proposed for debarment or otherwise determined to be ineligible under such law or convicted of a criminal offense related to the provision of health care items
or services, SCI shall notify Client in writing immediately. 
 11.2 Equipment and Material Ownership. Title to any and all equipment and other
materials procured by SCI pursuant to any Project-Specific Agreement on behalf of Client (“Equipment”) shall vest exclusively with Client, which shall have unencumbered rights, title and interest in all such Equipment at all times.
SCI shall deliver to Client copies of receipts for all Equipment. Client shall reimburse SCI for the actual amounts paid for such Equipment, plus, for any Equipment not procured from SCI’s existing stock, a five percent (5%) service fee.
SCI shall use commercially reasonable efforts in the selection, installation, maintenance, and proper operation of such Equipment. Upon completion of the Services for which Equipment is being utilized, Client may request that any remaining Equipment
be shipped to the destination of its choice. Any fees associated with such request, including the hourly fees for SCI personnel and all shipping costs, shall be the sole responsibility of Client. 

  
 12 

 11.3 Insurance. During the term of this Agreement, the Parties shall secure and maintain in full force and
effect commercially appropriate and standard insurance coverage for its responsibilities in connection with this Agreement and any applicable Project-Specific Agreement. Upon written request by either Party, the other Party shall provide proper
evidence showing that such insurance is in force. 
 11.4 Waiver. The failure of either Party hereto at any time or times to require performance of
any provision of this Agreement shall in no manner affect the right of such Party at a later time to enforce the same. No waiver by any Party hereto of any condition, or of the breach of any provision, term, covenant, representation, or warranty
contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or of the breach of any other provision, term, covenant,
representation or warranty of this Agreement. 
 11.5 Entire Understanding. This Agreement contains the entire agreement between the Parties with
respect to the subject matter thereof as of the Effective Date and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating to its subject matter, except that Project-Specific Agreements and other
similar service authorizations that have been properly executed prior to the Effective Date shall remain in full force and effect, and shall be construed, where possible, in accordance with the terms and conditions herein. 

11.6 Severability. If a court or other tribunal of competent jurisdiction holds any term or provision, or portion thereof, of this Agreement to be
invalid, void or unenforceable, the remaining provisions of the Agreement shall remain in full force and effect. It is the Parties’ intention that if a court or other tribunal holds any term or provision of this Agreement to be excessive in
scope, such term or provision shall be adjusted rather than voided, if possible. 
 11.7 Modification. This Agreement may not be amended or modified
except by written instrument signed by an authorized representative of the Parties. 
 11.8 Cooperation. Each Party shall execute and deliver all such
instruments and perform all such other acts as the other Party may reasonably request to carry out the transactions contemplated by this Agreement. 

11.9 Force Majeure. Neither Party shall be under any liability to the other hereunder on account of any loss, damage or delay occasioned or
caused by non-performance of any obligation under this Agreement due to circumstances beyond its reasonable control occurring after the Effective Date, including but not limited to, strikes, riots, fire, insurrection, war, natural disaster,
embargoes, failure of carriers, inability to obtain material or transportation facilities or changes in any law (“Force Majeure”). The Party affected by such a Force Majeure event is excused on a day-by-day basis to the extent of
the prevention; provided, that such Party notifies the other Party as soon as practicable of the nature and expected duration of the claimed Force Majeure event, uses all Commercially Reasonable Efforts to avoid or remove the causes of
non-performance and resume performance promptly after the causes have been removed. If a Party is unable to perform its obligations under this Agreement (other than the obligation to pay money) due to a Force Majeure event for a period in excess of
three (3) months (an “Extended Force Majeure Event”), then the other Party may terminate this Agreement with no further obligation to the non-performing Party. 

  
 13 

 11.10 Binding Effect. Subject to the restrictions on transfers, assignments and encumbrances set forth
herein, this Agreement shall inure to the benefit of and be binding upon the undersigned Parties and their respective legal successors. 
 11.11
Headings. All headings herein are for convenience only and shall not be construed as a limitation of the scope of the particular sections to which they refer. 

11.12 Assignment. Neither Party shall assign its rights under this Agreement without the prior written consent of the other Party, such consent not to
be unreasonably withheld, and any attempt to assign without such consent shall be void and of no effect. Notwithstanding the foregoing, either Party shall have the right to assign this Agreement, the Quality Agreement and all outstanding
Project-Specific Agreements hereunder in connection with the transfer or sale of all or substantially all of its business or assets related to this Agreement, or in the event of its merger, reorganization, consolidation, change in control or similar
transaction. 
 11.13 Non-solicitation. Each Party agrees not to solicit an employee of the other party who has performed any work in connection with
this Agreement, provided that newspaper, internet or other advertisements to fill job openings shall not be deemed to be a “solicitation” hereunder. This provision shall remain in effect during the term of this Agreement and for one
(1) year thereafter. Any exceptions to this provision must be in writing and signed by an authorized representative of each Party. 
 11.14 Surviving
Provisions. The Parties agree that the following provisions will survive the expiration or termination of this Agreement; the definitions contained herein to the extent such definitions pertain to terms in surviving provisions, Articles IV, V,
VII and IX in their entirety, and Articles 3.6 (with respect to Services performed prior to such expiration or termination), 10.3, 11.12, 11.14, 11.15. 

11.15 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to any
conflicts of laws provisions. In the event that an unresolved dispute arises over the enforcement, interpretation, construction, or breach of this Agreement, it shall be litigated in the State of Florida, within the U.S. District Court, Southern
District of Florida, or the Florida State Court, Broward County, 17th Judicial Circuit, and both Parties irrevocably submit to the exclusive jurisdiction of such courts for all purposes with respect to any legal action or proceeding in connection
with this Agreement. 
 11.16 Subcontractors and Assignees. SCI shall not have the right to subcontract or assign a third party to perform its
development and manufacturing obligations under this Agreement without the prior written consent of Client, which consent Client shall have the right to withhold for any reason in its sole discretion, provided that the Parties understand that SCI
may without such consent use subcontractors consultants, bound by appropriate confidentiality obligations, to assist or support its performance of this Agreement. For clarity, the provisions specified in this section shall not apply to third-party
API suppliers. 

  
 14 

 11.17 Taxes. Each Party is solely liable for costs, expenses, taxes, contributions or other charges
assessed against it against and its property. Each Party agrees to indemnify and hold the other Party and its directors, officers and employees harmless from and against any and all liability for its delay or failure to pay any such costs, expenses,
taxes, contributions or other charges. 
 11.18 Equitable Relief. The Parties acknowledge and agree that any actual or threatened breach of the
warranties or representations explicitly set forth in this Agreement will cause irreparable harm to the non-breaching Party; and therefore, the non-breaching Party will be entitled to equitable relief, including injunction and specific performance,
as a remedy for any such breach, where such relief shall not require posting bond or any other security or proof of actual damages or harm. Such equitable remedies shall not be deemed to be the exclusive relief for any such breach but shall be in
addition to all other remedies available in law or equity. 
 11.19 Legal Representation. This Agreement was negotiated by the Parties with the
benefit of legal representation. Any rule of construction or interpretation otherwise requiring this Agreement to be construed or interpreted against any Party shall not apply to any construction or interpretation hereof. 

11.20 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together
shall constitute one and the same instrument. 

  
 15 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized officers. 

 

									
	SANCILIO & COMPANY, INC.	 		  	 THERAPEUTICSMD, INC.
  

	 By:
	 	 /s/ Frederick D. Sancilio

Frederick D. Sancilio
 President and CEO
	 		  	By:	  	 /s/ Robert Finizio

Robert Finizio
 CEO

  
 16 

 EXHIBIT A 

Quality Agreement 

  
 17 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY “[****]” ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST,
AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

Exhibit B 
 Summary of Sancilio & Company, Inc.

 and TherapeuticsMD, Inc. 
 Agreements 

The following is a list of all active Agreements, SOW’s and Change Orders as determined at a meeting between the parties on December 11, 2014. 

 

					
	1.	  	May 17, 2012	  	Consulting Agreement.
			
	2.	  	May 17, 2012	  	Common stock purchase warrant (1,300,000 warrant shares at $2.57 subject to adjustment).
			
	3.	  	October 5, 2012    	  	Change order price quote.
		  		  	* stability program for *
		  		  	* stability program for *
		  		  	* stability program of *
		  		  	* stability program *
		  		  	Storage and testing.
		  		  	* stability program.
			
	4.	  	December 7, 2012	  	Change order price quote: VVA stability started.
			
	5.	  	January 15, 2013	  	Change order pricing quote:
		  		  	Stability programs for 3 additional PE combo exhibit batches.
		  		  	-Adjusted * strengths; change parts for encapsulation equipment to manufacture *
		  		  	-Low combo strengths *; change parts for encapsulation.
		  		  	-Cost of printing all caps.
		  		  	-* alone manufacturing process; substituting and exhibit batch of * in place of *
			
	6.	  	February 12, 2013	  	Change order price quote:
		  		  	-All placebo stability samples storage.
		  		  	-To meet combo clinical timelines and required volumes for P50 and P100.
		  		  	-* strength will require * that has not been manufactured.
		  		  	-* is required in greater numbers.

  
 18 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY “[****]” ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST,
AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

					
		  		  	-Supporting stability program *
		  		  	-Supporting stability program *
			
	7.	  	April 1, 2013	  	SOW:
		  		  	-up to * of a combo *
		  		  	-up to * of *
		  		  	-up to * of an *
			
	8.	  	April 30, 2013	  	Consulting Agreement. SCI to provide consulting services in support of Second generation estradiol and progesterone platform technology.
			
	9.	  	April 30, 2013	  	Amendment to 2012 Consulting Agreement.
			
	10.	  	May 7, 2013	  	Hormone topical cream development term sheet.
			
	11.	  	June 30, 2013	  	850,000 Common Stock Warrant.
			
	12.	  	November 15, 2013	  	SOW 3: Labor for second generation products: *
			
	13.	  	November 15, 2013    	  	First Amendment to SOW 3 (Clinical batches)
		  		  	-up to * of *
		  		  	-up to * of *
		  		  	-up to * of an *
		  		  	-up to * of a *
		  		  	-up to * of *
			
	14.	  	February 13, 2014	  	P & E Combo.
			
	15.	  	June 20, 2014	  	Change Order Pricing.
		  		  	One additional strength * for clinical trial.
			
	16.	  	October 22, 2014	  	NDA Product registration batch manufacturing for * of * to be used for NDA product registration.
			
	17.	  	January 6, 2015	  	NDA Product registration batch. For manufacturing and stability of *

  
 19EX-10.7

 Exhibit 10.7 

Consulting Agreement 

This Consulting Agreement (“Agreement”) by and between Sancilio and Company, Inc., a Florida corporation (“SCI”), and
TherapeuticsMD, Inc., a Nevada corporation (“Therapeutics”), is entered into as of May 17, 2012 (the “Effective Date”). Each of SCI and Therapeutics are referred to hereinafter as a ‘Party” and collectively as the
“Parties.” 
 WHEREAS, Therapeutics has requested SCI to provide certain consulting services (the “Consulting Services”)
as provided herein, and SCI is willing to provide the Consulting Services on the terms and subject to the conditions set forth in this Agreement, 

NOW THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 1. Consulting Services. SCI shall provide the
following Consulting Services to Therapeutics: 
 (a) services provided in support of Therapeutics’ drug development
efforts specifically pertaining to individual and combined hormone replacement drug products (“Drug Products “) including, but not limited to, services in support of Therapeutics’ ongoing and future drug development and
commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls (“CMC”) efforts, drug launch and post-approval activities, and other
intellectual property and know-how transfer associated therewith; 
 (b) services in support of Therapeutics’ efforts to
successfully obtain FDA Approval for the Drug Product described in Schedule I hereto; and 
 (c) other consulting services as
mutually agreed upon from time to time by SCI and Therapeutics in relation to new drug development opportunities. 
 The term “FDA
Approval,” as used herein, shall mean a marketing approval for commercial distribution in the United States pursuant to Section 505 of the Food, Drug and Cosmetic Act, as amended, For clarity, an “FDA Approval” as used herein
shall not include any “approvable” determinations by the U.S. Food & Drug Administration (“FDA”), including as set forth in any approvable letter under 21 CFR § 314.110. 

2. Expense Reimbursement. Therapeutics agrees to reimburse SCI for all out-of-pocket expenses for reasonable business-related travel
and engagement of experts required in the performance of the Consulting Services, provided however, that all such expenses shall be submitted in writing and pre-approved by Therapeutics prior to SCI incurring any such expense. All approved expenses
shall be paid within 15 days of presentation of invoices and appropriate documentation therefore. 

  
 1 

 3. Consulting Fee. No cash remuneration shall be paid hereunder. 

(a) In consideration for the Consulting Services to be provided pursuant to Section 1(a) hereof, Therapeutics agrees to issue and
deliver to SCI contemporaneously with the execution and delivery hereof, a five-year Common Stock Purchase Warrant (“Warrant”), in the form attached hereto as Exhibit A, granting SCI the right to purchase up to One million
three hundred thousand (1,300,000) shares of the Common Stock of Therapeutics (the “First Warrant”). The exercise price of the First Warrant shall be set at the five-day average closing bid price immediately preceding the execution of
this Agreement and all shares thereunder shall vest immediately upon issuance of the First Warrant. 
  

(b) Upon the receipt by Therapeutics of any final FDA Approval of a Drug Product, Therapeutics agrees to issue and deliver to SCI within five
(5) business days after receipt of FDA Approval, an additional five-year Warrant granting SCI the right to purchase Four hundred thirty-three thousand (433,000) shares of the Common Stock of Therapeutics (the “Second Warrant”).
The Exercise Price of the Second Warrant shall be set at the same price as the First Warrant outlined in Section 3(a) above and all shares thereunder shall vest immediately upon issuance of the Second Warrant. 

 
 (c) As incentive for SCI to specifically assist Therapeutics in obtaining
FDA Approval of the Drug Product described in Section 1(b), Therapeutics hereby agrees to issue and deliver to SCI a five-year Warrant granting SCI the right to purchase Four hundred thousand (400,000) shares of the Common Stock of
Therapeutics (the “Third Warrant”) upon the submission to FDA of the NDA pertaining to the Drug Product described in Schedule I. The Exercise Price of the Third Warrant shall be set at the five-day average closing bid price immediately
preceding the submission of the NDA to FDA and all shares thereunder shall vest immediately upon issuance of the Third Warrant. 
  

(d) SCI expressly acknowledges that the issuance of the aforementioned Warrants shall constitute full and adequate compensation for all
Consulting Services to be performed pursuant to this Agreement and that SCI shall not be entitled to any additional compensation in any form. For clarity, SCI shall not be entitled to seek additional consideration relative to any internal costs or
other obligations incurred by SCI relating to its Consulting Services (so called “soft costs”), including consulting, legal, engineering and infrastructure-related costs and obligations incurred by SCI in the performance of its duties
hereunder. 
  
 (e) If (i) the shares of the Common Stock of
Therapeutics shall be subdivided or combined into a greater or smaller number of shares or if Therapeutics shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional shares or new or different
shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock, the number of shares of Common Stock that may be purchased pursuant to each of the Warrants described in this
Section 3 shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made, including to the exercise price per share, to reflect such events. 

 
 4. Intellectual Property. Any invention, trade secret or know-how
and any materials, documents, programs or information belonging to Therapeutics and supplied to SCI by 

  
 2 

 
Therapeutics pursuant to this Agreement shall remain the property of Therapeutics, Any invention, trade secret or know-how and any materials, documents, programs or synthesis information
belonging to SCI prior to the date of this Agreement, or developed by SCI independently of this Agreement (i.e. not falling within Section 4.1 below), shall remain the property of SCI. 

 
 4.1 Any inventions (whether or not patentable), processes,
techniques, improvements, discoveries, designs, formulae, copyright, trademark, trade secrets, know-how, developments, confidential information, computer software, data and documentation, and all other intellectual property rights created,
discovered or reduced to practice by SCI solely or jointly in the course of performing the Consulting Services are collectively “Project IP.” SCI shall promptly notify Therapeutics in writing when it has made, created, or otherwise
invented any Project IP. SCI agrees to assign and hereby does assign to Therapeutics all Project IP (including any patent and all other intellectual property rights therein) and Project IP shall be deemed the Confidential Information of Therapeutics
for purposes of Section 5 below. SCI will take all reasonable steps and execute all documents that Therapeutics may reasonably request to transfer to and vest in Therapeutics the ownership and registration of all intellectual property rights
that may exist in such Project IP. 
  
 4.2 With respect
to Project IP, SCI will not knowingly or negligently incorporate or use therein any invention, discovery, process, technology or information that (a) is subject in whole or in part to a claim of any patent application or issued patent that is
owned or controlled by SCI, but not assigned to Therapeutics pursuant to Section 4 (“SCI Background Patent Rights”), (b is subject in whole or in part to a claim of any patent or patent application of a third party, or
(c) incorporates any SCI processes, inventions, techniques, know-how, or trade secrets that are owned or controlled by SCI, but not assigned to Therapeutics pursuant to Section 4 (“SCI Background Know-How”). In the event any
Project IP incorporates or requires the use of SCI Background Patent Rights or SCI Background Know-How (collectively, “SCI Proprietary Technology”), SCI shall grant and hereby grants to Therapeutics a non-exclusive, non-transferable,
worldwide, royalty-free, fully paid license to use such SCI Proprietary Technology in connection with the procurement, use, sale and marketing of any Drug Product or other products or processes deriving from this Agreement. 

 
 4.3 Therapeutics acknowledges that SCI is in the business
of providing other services for a variety of organizations other than Therapeutics. Accordingly, nothing in this Agreement shall preclude or limit SCI from providing other services or developing materials for itself or other clients, or from
utilizing the general knowledge gained during the course of its performance hereunder to perform similar services for other clients, provided that such provision of services or development of materials do not constitute a breach under Section 5
herein. 
  
 5. Confidentiality. During the performance of the
Consulting Services, SCI may receive from Therapeutics confidential or proprietary information, including information concerning Therapeutics’ regulatory submissions, pre-clinical and clinical trials; other data, testing and research
techniques, inventions, materials, processes, practices, product research, 

  
 3 

 
development and acquisition plans; acquisitions, mergers, divestitures and the like; other business and marketing plans; and other proprietary and trade secrets and like information (collectively
“Confidential Information”). Therapeutics agrees that it will only provide such Confidential Information to the extent that it is required by SCI to perform the Consulting Services. Notwithstanding the foregoing, the obligations of this
Section 5 shall not apply in the case of: 
  

	 	(i)	information of Therapeutics that is now in the public domain or which subsequently enters the public domain without fault on the part of SCI; or 

 
  

	 	(ii)	information of Therapeutics that is presently known by SCI from its own sources, where said present knowledge can be demonstrated by written records; or 

 
  

	 	(iii)	information of Therapeutics that SCI receives in good faith from a third party, where said third party is independent of Therapeutics and is under no obligation of confidentiality with respect to such information; or

  
  

	 	(iv)	information developed by or for SCI independent of the Consulting Services, or any other agreements with Therapeutics, and without the use of any Confidential Information of Therapeutics, as evidenced by SCI’s
written records. 

  
 5.1.1 SCI may disclose
Therapeutics’ Confidential Information to the extent required by law or order of a court or governmental agency or to enforce this Agreement; however, SCI must give Therapeutics prompt notice of such intended disclosure and SCI shall make a
commercially reasonable effort to obtain a protective order or otherwise protect the confidentiality of such Confidential Information. 
  

5.2 SCI agrees that without the express written consent of Therapeutics, it will not itself use, or provide to, disclose to, or
permit any third party to use said Confidential Information. SCI agrees to take commercially reasonable and appropriate measures to safeguard Confidential Information from theft, loss or negligent disclosure to others and to limit internal access to
Confidential Information to those of its employees, consultants, agents or subcontractors who reasonably require such access in order to accomplish performance of the Consulting Services. All SCI employees, consultants, agents or subcontractors who
have or will have access to Confidential Information have signed or, prior to disclosure of Confidential Information, will sign a confidentiality agreement with provisions no less protective than this Section 5. However, SCI assumes full
responsibility for the acts or omissions of such third-parties, no less than if the acts or omissions were those of SCI. 
  

5.3 Unless otherwise consented to by Therapeutics in writing, SCI agrees not to analyze for chemical composition any samples or
materials provided by Therapeutics, nor to allow or cause any such samples or materials to be released to third parties for analysis. 

  
 4 

 5.4 SCI shall not use or disclose to Therapeutics any information it knows to be
Confidential Information of a third party except as approved in advance in writing by Therapeutics. 
  

5.5 SCI agrees to notify Therapeutics promptly of the date of, and the circumstances involved in, the loss or unauthorized
disclosure of any Confidential Information of Therapeutics. 
  

5.6 Upon termination of this Agreement, and at the written direction of Therapeutics, SCI will promptly return all of
Therapeutics’ Confidential Information, including any documents prepared by SCI that contain such information. SCI may retain a single archival copy of the Confidential Information for the sole purpose of determining the scope of obligations
incurred under this Agreement. 
  
 5.7 Except for
disclosure as may be required by regulatory authorities, the Parties agree that they shall not use the other Party’s name, or disclose the existence of this Agreement or any matters relating to the Services provided hereunder in any
advertising, promotion, written articles or communications without the prior written consent of the other Party, which consent shall not to be unreasonably withheld. 
  

5.8 The obligations of this Section 5 shall apply to all Confidential Information, whether such Confidential Information
was disclosed before or after the Effective Date, and shall survive indefinitely unless specifically excluded under Section 5.1 (i)-(iv). 

6. Indemnification. 

6.1 Indemnification by Therapeutics. Subject to Section 6.3 below, Therapeutics shall indemnify and hold harmless
SCI, its agents, employees, directors and Affiliates from any loss, expense and liability, including reasonable attorney’s fees arising out of Therapeutics’ negligence or willful misconduct under this Agreement, except to the extent the
claim, suit or proceeding is subject to SCI’s indemnification obligations in Section 6.2 below. 
 6.2
Indemnification by SCJ. Subject to Section 6.3 below, SCI shall indemnify and hold harmless Therapeutics, its agents, employees, directors and Affiliates from any loss, expense and liability, including reasonable attorney fees arising out of
SCI’s negligence or willful misconduct in the course of providing Consulting Services pursuant to this Agreement. 
  

6.3 A Party that intends to claim indemnification (the “Indemnitee”) under Section 6.1 or 6.2 shall promptly
notify the other party (the “Indemnitor”) in writing of any claim, complaint, suit, proceeding or cause of action with respect to which the Indemnitee intends to claim such indemnification (for purposes of this Section 6, each a
“Claim”), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or
settlement of such Claim. The Indemnitor shall not settle any Claim without the consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed. The Indemnitee, and its 

  
 5 

 
employees, at the Indemnitor’s request and expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered
by this indemnification. 
 6.4 SCI shall be responsible for the safety of its own employees and agents with respect to the
handling or use of materials involved in the performance of this Agreement. 
 7. SCI represents and warrants to Therapeutics as of the
Effective Date that: 
  
 (a) the execution and delivery
of this Agreement and the performance of the transactions, rights and licenses contemplated hereby have been duly authorized by all appropriate SCI corporate action; 
  

(b) SCI has the full right and authority to enter into this Agreement, and is a legal and valid obligation binding upon SCI and
enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by the terms set forth herein, and does not conflict with any agreement, instrument or understanding to which SCI is a party or by which it is
bound; 
  
 (c) SCI has the full right and legal capacity
to grant the rights granted to Therapeutics hereunder without violating the rights of any third party; and 
  

(d) SCI is the owner of any SCI technology and Project IP, SCI Background Patent Rights, and SCI Proprietary Technology
conveyed and that it is aware of no actual or threatened third party claims of ownership of the same. 
  

8. Term. The term of this Agreement (“Term”) shall commence as of the Effective Date and continue until the time of the
commercial manufacture of a Drug Product. The Term may be extended by mutual, written agreement between the Parties. 
  

9. Assignment. Neither party hereto may assign this Agreement, in whole or in part; without the prior written consent of the other party
hereto. 
  
 10. Notices. 

(a) All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon
personal delivery to the party to be notified, (ii) when sent by facsimile, upon written confirmation of receipt by addressee, (iii) five days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. 

(b) Notices shall be sent to each party at its respective address listed below (if a party desires to change its address for
notice, it shall notify the other party according to these terms): 
  

			
	              If to SCI:	 	 Sancilio and Company, Inc.
 Attn: Fred Sancilio,
President & CEO
 3874 Fiscal Court, Suite 200

		 	 Riviera Beach, Florida 33404
 Facsimile No:
(561) 847-2312

  
 6 

			
		
	            If to Therapeutics:	 	 TherapeuticsMD, Inc.
 Attn: Robert Finizio,
CEO
 951 Broken Sound Parkway NW, Suite 320
 Boca Raton, FL
33487
 Facsimile No: (561) 431-3389

  
 11. Records & Audits. SCI
agrees to maintain records of all Consulting Services performed under this Agreement in accordance with the FDA’s archival guidelines. Therapeutics may review the records of SCI relating to the Consulting Services performed and expenses
incurred to assure compliance with all provisions of this Agreement, provided that such inspection may take place (i) only upon reasonable prior written notice (not less than ten (10) business days) and during SCI’s regular business
hours. 
  
 11.1 Upon reasonable prior written notice (not
less than fifteen (15) business days) and during regular business hours, Therapeutics may, at its own cost and expense, review SCI’s quality control procedures and records, with a representative of SCI present. 

 
 11.2 In the event of an inspection by any governmental or
regulatory authority concerning the Consulting Services performed hereunder, SCI shall notify Therapeutics promptly upon learning of such an inspection, shall supply Therapeutics with copies of any correspondence or portions or correspondence
relating to the Consulting Services and shall inform Therapeutics of the general findings and outcomes of such inspections. 
 12.
Certification. SCI represents, warrants and certifies that neither it, nor its Affiliates, nor any of their respective directors, officers, principals, employees and agents was or is debarred, suspended, proposed for debarment or otherwise
determined to be ineligible to participate in the drug industry, federal health care programs under or convicted of a criminal offense related to the provision of health care items or services the United States Food, Drug and Cosmetic Act (21 U.S.C.
301 et seq.), and that it has not and will not use in any capacity the services of any entity or person debarred under such law with respect to Consulting Services to be performed under this Agreement. In the event that SCI, or any of its
affiliates, directors, officers, principals, employees, or agents becomes or is debarred, suspended, proposed for debarment or otherwise determined to be ineligible to participate in the drug industry under such law or convicted of a criminal
offense related to the provision of health care items or services, SCI shall notify Therapeutics in writing immediately. 
 13.
Waiver. The failure of either Party hereto at any time or times to require performance of any provision of this Agreement shall in no manner affect the right of such Party at a later time to enforce the same. No waiver by any Party hereto of
any condition, or of the breach of any provision, term, covenant, representation, or warranty contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing
waiver of any such condition or of the breach of any other provision, term, covenant, representation or warranty of this Agreement. 
 14.
Entire Understanding. This Agreement contains the entire agreement between the Parties with respect to the subject matter thereof as of the Effective Date. 

15. Severability. If a court or other tribunal of competent jurisdiction holds any term or provision, or portion thereof, 

  
 7 

 
of this Agreement to be invalid, void or unenforceable, the remaining provisions of the Agreement shall remain in full force and effect. It is the Parties’ intention that if a court or other
tribunal holds any term or pro-vision of this Agreement to be excessive in scope, such term or provision shall be adjusted rather than voided, if possible. 

16. Modification. This Agreement may not be amended or modified except by written instrument signed by an authorized representative of
the Parties. 
 17. Cooperation. Each Party shall execute and deliver all such instruments and perform all such other acts as the
other Party may reasonably request to early out the transactions contemplated by this Agreement. 
 18. Governing Law. This Agreement
shall be governed by and construed in accordance with the laws of the State of Florida without regard to any conflict of law provisions. In the event that an unresolved dispute arises over the enforcement, interpretation, construction, or breach of
this Agreement, it shall be litigated in the State of Florida, within the U.S. District Court, Southern District of Florida, or the Florida State Court, Broward County, 17th Judicial Circuit, and both Parties irrevocably submit to the exclusive
jurisdiction of such courts for all purposes with respect to any legal action or proceeding in connection with this Agreement. 
 19.
“Affiliate” as used herein shall mean any corporation, company, partnership, joint venture and/or firm, which controls, is controlled by or is under common control with a Party. For purposes of this Section 19,
“control” shall mean (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; and (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to substantially direct the management and policies of such non-corporate entities. 

 
 20. Counterparts; Signatures. This Agreement may be signed in one
or more counterparts, each of which shall be one and the same agreement. If a counterpart of this Agreement is signed and transmitted via facsimile, or via PDF transmitted by e-mail, such signatures shall bind the signing party to this Agreement in
full. Original documents may also be signed by the parties and will have the same binding power. 
 21. Independent Parties. This
Agreement shall not be construed as constituting a joint venture or partnership between SCI and Therapeutics. No party shall have any right to obligate any other party in any manner whatsoever, and nothing herein is intended to confer any right of
any kind to any third person. 
 [Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, the parties have each caused this Agreement to be signed and delivered by
their duly authorized representatives as of the Effective Date. 
  

	
	 Sancilio and Company, Inc.
  

By: /s/Fred Sancilio
 Fred
Sancilio
 President & CEO

	 TherapeuticsMD, Inc.
  

By: /s/Robert Finizio
 Robert
Finizio
 Chief Executive Officer

  
 9 

 Exhibit A 

Form of Warrant 

  
 10 

 SCHEDULE I 

An estradiol-based Drug Product with a dosage equal to or lower than one-half (1/2) of the lowest effective dose of the product currently known as
Estrace, while achieving substantially identical bioequivalence. 

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]